Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma.

ABSTRACT:

Purpose

Oligoprogression, defined as limited sites of progression on systemic therapy, in patients with metastatic renal cell carcinoma (mRCC) is not uncommon, possibly because of inter- and intratumoral heterogeneity. We evaluated the effect of stereotactic ablative radiation therapy (SAbR) for longitudinal control of oligoprogressive mRCC.

Methods and materials

Patients with extracranial mRCC were included in this retrospective analysis if they progressed in ≤3 sites on systemic therapy while demonstrating response/stability at other sites and received SAbR to all progressing sites without switching systemic therapy. Our primary endpoint was modified progression-free survival (mPFS), which we calculated from the start of SAbR to the start of a subsequent systemic therapy,

SUBMITTER: Schoenhals JE 

PROVIDER: S-EPMC8498727 | biostudies-literature | 2021 Sep-Oct

REPOSITORIES: biostudies-literature